MedTrace Logo

Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma

NCT01864759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-08-29

No results posted yet for this study

Summary

The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally replicative or oncolytic adenovirus.

Conditions

  • Locally Advanced or Metastatic Melanoma

Interventions

BIOLOGICAL

ICOVIR-5

Sponsors & Collaborators

  • Institut Català d'Oncologia

    lead OTHER

Principal Investigators

  • Ramon Salazar, MD PhD · Institut Català d'Oncologia

  • Ramon Alemany, PhD · Institut Català d'Oncologia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-11
Primary Completion
2016-12-20
Completion
2017-04-26

Countries

  • Spain

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01864759 on ClinicalTrials.gov